PLATFORM

  • home
  • Platform
  • UniStac®

UniStac®

Medical unmet need for complex diseases

Our proprietary UniStac® platform uses two different mammalian cells or bacterial cells to produce two smaller proteins. They are then combined into a single Y-shaped multifunctional biologics through enzyme-mediated conjugation.

Innovation to speed multi-targeting drug to patients

Key Benefits

01
Fast and cost-effective development
  • Our UniStac® platform allows generating hit trispecific molecules in just six months. This development speed is made possible by our engineered enzymatic reaction, which mechanistically prevents the formation of homodimers. Additionally, our conjugation process is highly site-specific, which means we can ensure the complete prevention of any unwanted isoforms. Homodimers and isoforms are typically considered time-consuming and challenging obstacle in drug development.
02
True plug-and-play
  • Developing drugs that target multiple targets simultaneously can be a daunting task, as it requires exploring a vast number of possible combinations. However, the UniStac® platform provides a highly modular approach, allowing for off-the-shelf binders to be mixed and matched to easily create new combinations that can be tested.
03
Robust manufacturingprocess
  • Manufacturing trispecific antibodies can be even more challenging than bispecifics due to their larger size and complex structure. However, UniStac® simplifies this complexity by dividing it into two separate proteins that are conjugated. This approach minimizes the risk of reduced yields for more complex molecules and makes the process of developing trispecific antibodies more efficient and effective.
TOP